April, 7 2021<\/p>\n\n\n\n
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information. Time: 8:45 PM<\/p>\n\n\n\n
In connection with the approval dated today of the financial statements of Celon Pharma S.A. (the \u201cCompany\u201d) prepared in accordance with International Financial Reporting Standards (“IFRS”), covering the year which ended on December 31, 2020 and including comparative data for the years which ended on December, 31 2019 and December 31, 2018, the Management Board of the Company makes the aforementioned report public. Due to the fact that IFRS accounting policies were applied for the first time, the opening balance of the earliest period, i.e., January 1, 2018, which is also the date of transition to IFRS, is also presented in the statements.<\/p>\n\n\n\n
The report has been prepared pursuant to Resolution No. 9\/2021 of the Extraordinary General Meeting of the Company of February, 16 2021, where it was resolved that additional financial statements of Celon Pharma S.A. would be performed in accordance with IFRS for the financial years 2018-2020, for the purpose of drawing up the Company’s prospectus, in connection with the public offering and application for admission to trading on the regulated market operated by the Warsaw Stock Exchange S.A. of new issue shares of Celon Pharma S.A., issued within the framework of the authorized share capital referred to in Resolution No. 4\/2021 of this Extraordinary General Meeting.<\/p>\n\n\n\n
The Management Board of the Company advises that the first period for which the annual financial statements of the Company will be prepared for statutory purposes in accordance with IFRS \u2013 in accordance with the stores ( aforementioned adopted Resolution No. 9\/2021 of the Extraordinary General Meeting \u2013 is the financial year commencing on January 1, 2021, while the financial statements of the Company for 2020 (published on March, 31 2021) and the statements for the earlier periods were prepared in accordance with Polish Accounting Standards. The effects of the transition to IFRS for the particular items in the Company’s statement of financial position as at January 1, 2018 and December 31, 2020 and the statement of comprehensive income and statement of cash flows for the period from January 1 to December 31, 2018 and for the period from January 1 to December 31, 2020 are presented in the appendix to this current report, in note No. 8.<\/p>\n","protected":false},"excerpt":{"rendered":"